Why Shopify Was Climbing Today
Needham weighed in with a buy rating on Shopify, and Baird raised its price target.
The company has performed well in an uncertain consumer environment.
Analysts are expecting another round of solid growth when the company reports second-quarter earnings in a few weeks.
10 stocks we like better than Shopify ›
Shares of Shopify (NASDAQ: SHOP) were moving higher today after the e-commerce software superstar picked up some new fans on Wall Street.
Shopify scored a buy rating from Needham, and another analyst raised their price target on the growth stock.
As of 1:48 p.m. ET, the stock was up 4.2% on the news.
Shopify earns more cheers
Needham became the latest research firm to weigh in positively on Shopify, calling the stock a buy with a price target of $135.
The firm observed that Shopify was in the middle of a durable growth cycle, benefiting from continuing growth in consumer spending, despite weak sentiment, and it's likely to benefit from the recently signed U.S. tax bill.
Additionally, Baird raised its price target on the stock from $110 to $120, and maintained an outperform rating as analyst Colin Sebastian said that its merchant business remains healthy despite headwinds on its monthly recurring revenue.
What's next for Shopify
Shopify has a lot of exposure to the business cycle and broader consumer demand, but its continued growth in the face of concerns about a trade war is a positive sign.
The opportunity in front of the company still seems sizable as it innovates and invests in AI, and continues to attract new merchants to the platform.
Investors will want to pay attention tomorrow morning when the June Consumer Price Index is released, as that could move the stock. Investors are still anxious to see if tariffs have had any impact on prices thus far. A few weeks later, Shopify will report second-quarter earnings. Analysts expect revenue to jump 24.5% to $2.55 billion, and see adjusted earnings per share improving from $0.26 to $0.29.
Should you invest $1,000 in Shopify right now?
Before you buy stock in Shopify, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!*
Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 14, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
AECOM announces cash tender offer for any and all 5.125% Senior Notes due 2027
AECOM (NYSE: ACM) today announced that it has commenced a cash tender offer (the 'Tender Offer') for any and all of its $997,293,000 principal amount outstanding 5.125% Senior Notes due 2027 (the 'Notes'). A comprehensive description of the terms of the Tender Offer is included in AECOM's Offer to Purchase, dated July 15, 2025 (the 'Offer to Purchase'), and the related Notice of Guaranteed Delivery (the 'Notice of Guaranteed Delivery' and, together with the Offer to Purchase, the 'Offer Documents'). The following table summarizes the material pricing terms of the Tender Offer, which is being made upon, and is subject to, the terms and conditions set forth in the Offer Documents. CUSIP Nos Outstanding Principal Amount Title of Notes U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread 00774CAB3 00774CAA5 U0081CAA0 $997,293,000 5.125% Senior Notes due 2027 4.375% due December 15, 2026 PX4 50 bps The Tender Offer will expire at 5:00 p.m., New York City time, on July 21, 2025, unless extended or earlier terminated by AECOM (the 'Expiration Date'). No tenders submitted after the Expiration Date will be valid unless delivered pursuant to the guaranteed delivery procedures described in the Offer to Purchase at or prior to 5:00 p.m., New York City time, on July 23, 2025 (the 'Guaranteed Delivery Date'). Tenders of Notes may be withdrawn any time at or prior to 5:00 p.m., New York City time, on July 21, 2025, by following the procedures described in the Offer to Purchase. The consideration (the 'Total Consideration') offered for each $1,000 principal amount of the Notes validly tendered and not validly withdrawn and accepted for purchase pursuant to the Tender Offer will be determined in the manner described in the Offer to Purchase by reference to the fixed spread for the Notes specified in the table above plus the yield to December 15, 2026, based on the bid-side price of the Reference Security specified in the table above, as quoted on the Bloomberg Bond Trader PX4 page as of 11:00 a.m., New York City time, on July 21, 2025, unless extended or earlier terminated by AECOM. In addition to the Total Consideration, AECOM will also pay accrued and unpaid interest up to, but not including, the Initial Settlement Date (as defined below). The settlement date for Notes validly tendered and not validly withdrawn and accepted for purchase and delivered at or prior to the Expiration Date is expected to be July 22, 2025, the next business day after the Expiration Date (the 'Initial Settlement Date'). The settlement date for Notes delivered pursuant to the guaranteed delivery procedures described in the Offer to Purchase is expected to be July 24, 2025, the next business day after the Guaranteed Delivery Date (the 'Guaranteed Delivery Settlement Date'). For the avoidance of doubt, accrued interest will cease to accrue on the Initial Settlement Date for all Notes accepted in the Tender Offer, whether such Notes are purchased on the Initial Settlement Date or the Guaranteed Delivery Settlement Date. Holders must validly tender (and not validly withdraw) their Notes at or prior to the Expiration Date, or deliver a properly completed and duly executed Notice of Guaranteed Delivery for their Notes at or prior to the Expiration Date, and tender their Notes at or prior to the Guaranteed Delivery Date (as defined in the Offer to Purchase), in accordance with the instructions set forth in the Offer to Purchase, in order to be eligible to receive the Total Consideration. AECOM's obligation to accept for purchase and to pay for the Notes validly tendered and not validly withdrawn pursuant to the Tender Offer is subject to the satisfaction or waiver of certain conditions, which are more fully described in the Offer to Purchase, including, among others, AECOM having raised net proceeds from its concurrently commenced offering of $1,000,000,000 in aggregate principal amount of its senior unsecured notes due 2033 (the 'New Notes Offering'), which, together with cash on hand or other immediately available funds, are sufficient to fund the purchase of all Notes validly tendered and accepted for purchase in the Tender Offer (such condition, the 'Financing Condition'). In addition, concurrently with the pricing of the New Notes Offering, the Company intends to issue a conditional notice of redemption to the holders of the Notes to redeem any and all Notes that remain outstanding after completion of the Tender Offer at a make-whole redemption price based on a make-whole spread of 50 basis points over the yield of the Reference Security specified above, calculated pursuant to the applicable provisions of the indenture governing the Notes, plus accrued and unpaid interest to, but not including, the date of redemption. The date of redemption is expected to be August 14, 2025 (the 'Redemption Date'). The redemption of any and all Notes that remain outstanding after completion of the Tender Offer will be made in accordance with the provisions of the Indenture, and will be conditioned upon the satisfaction of the Financing Condition. The Tender Offer does not constitute an offer to sell or a solicitation of an offer to buy any securities or other financial instruments that may be issued or otherwise incurred in connection with the New Notes Offering. AECOM reserves the right, subject to applicable law, in its sole discretion, to: (i) waive any and all conditions to the Tender Offer at any time and from time to time; (ii) extend or terminate the Tender Offer; or (iii) otherwise amend the Tender Offer in any respect. AECOM is not soliciting consents from holders of securities in connection with the Tender Offer. AECOM has retained BofA Securities to act as exclusive Dealer Manager for the Tender Offer. D.F. King and Co., Inc. has been retained to serve as both the tender and information agent (the 'Tender and Information Agent') for the Tender Offer. For additional information regarding the terms of the Tender Offer, please contact: BofA Securities at debt_advisory@ (email), (888) 292-0070 (toll free) or (646) 743-2120 (collect). Requests for copies of the Offer to Purchase and other related materials should be directed to D.F. King and Co., Inc. at aecom@ (email), (888) 887-0082 (U.S. Toll Free), (212) 365-6884 (Banks and Brokers). Copies of the Offer to Purchase and Notice of Guaranteed Delivery are available at the following web address: This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to sell with respect to any Notes nor is this announcement an offer to sell or a solicitation of an offer to purchase new debt securities, or a notice of redemption of the Notes. The Tender Offer is being made solely pursuant to the Offer Documents, which set forth the complete terms and conditions of the Tender Offer. The Tender Offer is not being made to, nor will AECOM accept tenders of Notes from, holders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. None of AECOM, its affiliates, their respective board of directors, the Dealer Manager, the trustee of the Notes or the Tender and Information Agent makes any recommendation to any holder of Notes in connection with the Tender Offer. Holders must make their own decisions as to whether to tender their Notes and, if so, the principal amount of Notes to tender. About AECOM AECOM (NYSE: ACM) is the global infrastructure leader, committed to delivering a better world. As a trusted professional services firm powered by deep technical abilities, we solve our clients' complex challenges in water, environment, energy, transportation and buildings. Our teams partner with public- and private-sector clients to create innovative, sustainable and resilient solutions throughout the project lifecycle – from advisory, planning, design and engineering to program and construction management. AECOM is a Fortune 500 firm that had revenue of $16.1 billion in fiscal year 2024. Cautionary Note Regarding Forward-Looking Statements All statements in this press release other than statements of historical fact are 'forward-looking statements' for purposes of federal and state securities laws, including any statements of the plans, strategies and objectives for future operations, profitability, strategic value creation, capital allocation strategy including stock repurchases, risk profile and investment strategies, and any statements regarding future economic conditions or performance, and the expected financial and operational results of AECOM. Although AECOM believes that the expectations reflected in these forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of these forward-looking statements. Important factors that could cause AECOM's actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in these forward-looking statements include, but are not limited to, the following: AECOM's business is cyclical and vulnerable to economic downturns and client spending reductions; potential government shutdowns, changes in administration or other funding directives and circumstances that may cause governmental agencies to modify, curtail or terminate AECOM's contracts; government contracts are subject to audits and adjustments of contractual terms; long-term government contracts and subject to uncertainties related to government contract appropriations; losses under fixed-price contracts; limited control over operations that run through AECOM's joint venture entities; liability for misconduct by AECOM's employees or consultants; changes in government laws, regulations and policies, including failure to comply with laws or regulations applicable to AECOM's business; maintaining adequate surety and financial capacity; potential high leverage and inability to service AECOM's debt and guarantees; ability to continue payment of dividends; exposure to political and economic risks in different countries, including tariffs and trade policies, geopolitical events, and conflicts; inflation, currency exchange rates and interest rate fluctuations; changes in capital markets and stock market volatility; retaining and recruiting key technical and management personnel; legal claims and litigation; inadequate insurance coverage; environmental law compliance and inadequate nuclear indemnification; unexpected adjustments and cancellations related to AECOM's backlog; partners and third parties who may fail to satisfy their legal obligations; managing pension costs; AECOM Capital real estate development; cybersecurity issues, IT outages and data privacy; risks associated with the benefits and costs of the sale of AECOM's Management Services and self-perform at-risk civil infrastructure, power construction and oil and gas construction businesses, including the risk that any purchase adjustments from those transactions could be unfavorable and any future proceeds owed to us as part of the transactions could be lower than we expect; as well as other additional risks and factors that could cause actual results to differ materially from these forward-looking statements set forth in AECOM's reports filed with the Securities and Exchange Commission. Any forward-looking statements are made as of the date hereof. AECOM does not intend, and undertakes no obligation, to update any forward-looking statement.
Globe and Mail
13 minutes ago
- Globe and Mail
Metastatic Urothelial Carcinoma Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Metastatic Urothelial Carcinoma Pipeline Insight, 2025' report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Metastatic Urothelial Carcinoma pipeline landscape. It covers the Metastatic Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Metastatic Urothelial Carcinoma Research. Learn more about our innovative pipeline today! @ Metastatic Urothelial Carcinoma Pipeline Outlook Key Takeaways from the Metastatic Urothelial Carcinoma Pipeline Report In July 2025, Inovio Pharmaceuticals announced a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). In July 2025, Merck Sharp & Dohme LLC conducted a substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments. In July 2025, Seagen organized a study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. DelveInsight's Metastatic Urothelial Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Metastatic Urothelial Carcinoma treatment. The leading Metastatic Urothelial Carcinoma Companies such as PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others. Promising Metastatic Urothelial Carcinoma Pipeline Therapies such as BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others. Stay informed about the cutting-edge advancements in Metastatic Urothelial Carcinoma treatments. Download for updates and be a part of the revolution in oncology Care @ Metastatic Urothelial Carcinoma Clinical Trials Assessment Metastatic Urothelial Carcinoma Emerging Drugs Profile MFA 370: Ectin Research AG Urothelial bladder cancer is one of the world's most aggressive cancers, current treatments can be tough to tolerate. MFA-370 is planned to be a simple oral tablet developed to eliminate tumors safely, with few if any side effects. MFA-370 is a combination of a medication from that substance family, together with one other standard, well-established drug. Both are tried, tested and trusted treatments that have already undergone large-scale clinical trials. It already demonstrated efficacy in preclinical results and 'patient zero' case. In addition to MFA-370 showing positive preclinical results in metastatic urothelial bladder cancer, it has also eliminated prostate, breast and colorectal cancer cells in preclinical tests too. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma. XL 092: Exelixis XL092 is a next-generation oral TKI that builds on our extensive experience with cabozantinib. XL092 also targets VEGF receptors, MET, TAM kinases and other kinases implicated in cancer's growth and spread. In preclinical tumor models, XL092 showed excellent activity as a single agent and in combination with ICIs. XL092 also has an optimized pharmacokinetic profile aimed at facilitating adverse event management in the clinic. XL092 is the first new Exelixis-discovered compound to come out of the company's reinitiated drug discovery activities, which entered phase 1 clinical development in 2019. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma. Lurbinectedin: PharmaMar Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds. Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma. The Metastatic Urothelial Carcinoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Urothelial Carcinoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Urothelial Carcinoma Treatment. Metastatic Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Metastatic Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Urothelial Carcinoma market. Learn more about Metastatic Urothelial Carcinoma Drugs opportunities in our groundbreaking Metastatic Urothelial Carcinoma research and development projects @ Metastatic Urothelial Carcinoma Unmet Needs Metastatic Urothelial Carcinoma Companies PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others. Metastatic Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Metastatic Urothelial Carcinoma Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Discover the latest advancements in Metastatic Urothelial Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Metastatic Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives Scope of the Metastatic Urothelial Carcinoma Pipeline Report Coverage- Global Metastatic Urothelial Carcinoma Companies- PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others. Metastatic Urothelial Carcinoma Pipeline Therapies- BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others. Metastatic Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Metastatic Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Urothelial Carcinoma Pipeline on our website @ Metastatic Urothelial Carcinoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Metastatic Urothelial Carcinoma: Overview Pipeline Therapeutics Therapeutic Assessment Metastatic Urothelial Carcinoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name : Company name Drug profiles in the detailed report….. Mid Stage Products (Phase II) Lurbinectedin: PharmaMar Drug profiles in the detailed report….. Early Stage Products (Phase I) XL 092: Exelixis Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Inactive Products Metastatic Urothelial Carcinoma Key Companies Metastatic Urothelial Carcinoma Key Products Metastatic Urothelial Carcinoma- Unmet Needs Metastatic Urothelial Carcinoma- Market Drivers and Barriers Metastatic Urothelial Carcinoma- Future Perspectives and Conclusion Metastatic Urothelial Carcinoma Analyst Views Metastatic Urothelial Carcinoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
13 minutes ago
- Globe and Mail
Lamb Weston Holdings Announces Quarterly Dividend
The Board of Directors of Lamb Weston Holdings, Inc. (NYSE: LW) today declared a quarterly dividend of $0.37 per share of Lamb Weston common stock. The dividend is payable on August 29, 2025, to stockholders of record as of the close of business on August 1, 2025. About Lamb Weston Lamb Weston is a leading supplier of frozen potato products to restaurants and retailers around the world. For 75 years, Lamb Weston has led the industry in innovation, introducing inventive products that simplify back-of-house management for its customers and make things more delicious for their customers. From the fields where Lamb Weston potatoes are grown to proactive customer partnerships, Lamb Weston always strives for more and never settles. Because, when we look at a potato, we see possibilities. Learn more about us at
